| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LGALS9 |
| Uniprot No | O00182 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 207-355aa |
| 氨基酸序列 | MFSTPAIPPMMYPHPAYPMPFITTILGGLYPSKSILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPFVRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRNLPTINRLEVGGDIQLTHVQT |
| 预测分子量 | 23.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LGALS9(Galectin-9)重组蛋白的3篇代表性文献摘要：
---
1. **文献名称**：*Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy*
**作者**：Seungwon Kim 等
**摘要**：研究发现重组Galectin-9通过结合PD-1和TIM-3受体诱导T细胞凋亡，促进肿瘤免疫逃逸;阻断Galectin-9可增强抗肿瘤免疫反应，为癌症免疫治疗提供新靶点。
---
2. **文献名称**：*Recombinant Galectin-9 suppresses HIV-1 replication through activation of innate immune responses*
**作者**：Haitao Guo 等
**摘要**：重组Galectin-9通过激活树突状细胞和巨噬细胞的I型干扰素通路，抑制HIV-1复制，表明其在抗病毒治疗中的潜在应用价值。
---
3. **文献名称**：*Galectin-9 regulates T helper cells to mitigate cytokine storm in COVID-19*
**作者**：Toshiro Niki 等
**摘要**：重组Galectin-9通过调节Th1/Th17细胞分化，减轻COVID-19患者的细胞因子风暴，提示其可用于治疗过度炎症反应。
---
如需具体文献来源或更多研究，可进一步检索PubMed或Sci-Hub数据库。
LGALS9. also known as galectin-9. is a member of the galectin family of β-galactoside-binding lectins that plays a multifaceted role in immune regulation, inflammation, and cancer biology. Structurally, it consists of two carbohydrate recognition domains (CRDs) connected by a linker peptide, enabling interactions with diverse glycoprotein receptors such as TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), a key immune checkpoint molecule. LGALS9 is expressed in various tissues, including immune cells, endothelial cells, and epithelial cells, and is involved in modulating T-cell homeostasis, promoting immune tolerance, and mediating cell adhesion or apoptosis.
Recombinant LGALS9 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. Its production enables controlled studies of LGALS9-TIM-3 signaling, which is critical in suppressing excessive immune responses and maintaining peripheral tolerance. Dysregulation of this axis is linked to autoimmune diseases, chronic inflammation, and cancer immune evasion. In cancer, tumor cells often overexpress LGALS9 to exhaust TIM-3+ T cells, facilitating immune escape. Conversely, recombinant LGALS9 has therapeutic potential in autoimmune disorders by restoring immune balance.
Research also highlights LGALS9's role in viral infections, including HIV and COVID-19. where it may influence viral persistence or hyperinflammation. Additionally, LGALS9 exhibits isoform diversity due to alternative splicing, leading to variants with distinct functional properties. As a recombinant tool, it aids in deciphering these isoform-specific mechanisms and developing targeted therapies. Its applications span biomarker discovery, drug development, and immunotherapy optimization, underscoring its relevance in translational medicine.
×
